Yuxin Zhou , Qian Wang , Qian Wang , Ziyi Zhou , Xiaoyang Peng , Botao Qu , Ruiping Zhang
{"title":"Self-assembled copper chlorogenic acid nanoparticles: Inducing pyroptosis and cuproptosis to activate antitumor immunity","authors":"Yuxin Zhou , Qian Wang , Qian Wang , Ziyi Zhou , Xiaoyang Peng , Botao Qu , Ruiping Zhang","doi":"10.1016/j.jconrel.2025.113941","DOIUrl":null,"url":null,"abstract":"<div><div>Currently, the tumor treatment faces many challenges. Although chemotherapy is the most effective and economical choice, most chemotherapy drugs lack tumor specificity, have low bioavailability, and face many obstacles in clinical application. Significantly, the tumor immunosuppressive microenvironment (TIME) and low immunogenicity in solid tumors also seriously affect the clinical effect of tumor therapy. Here, metal-phenolic network nanoparticles self-assembled by copper-coordinated natural drug chlorogenic acid (ChA) (ChA-Cu NPs) are designed to amplify cell immunogenic death mediated by cuproptosis and pyroptosis for antitumor immunotherapy. Specifically, the synthesized ChA-Cu NPs can disintegrate and release Cu<sup>2+</sup> and the polyphenol drug ChA in the tumor microenvironment, realizing the combined chemotherapy/chemodynamic kinetics in the treatment of tumors. Importantly, the release of Cu<sup>2+</sup> and ChA can drive the cascade reaction, which can disturb redox homeostasis by producing reactive oxygen species (ROS) and depleting GSH, and induce pyroptosis and make tumor cells more sensitive to cuproptosis. Furthermore, pyroptosis and cuproptosis can evoke immunogenic cell death (ICD) and release damage-associated molecular patterns (DAMPs), stimulating dendritic cells (DCs) to mature and activate CD8<sup>+</sup> T cells. It is encouraging that ChA-Cu NPs can reprogram TIME to achieve significant tumor growth inhibition.</div></div>","PeriodicalId":15450,"journal":{"name":"Journal of Controlled Release","volume":"384 ","pages":"Article 113941"},"PeriodicalIF":10.5000,"publicationDate":"2025-06-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Controlled Release","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0168365925005619","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, MULTIDISCIPLINARY","Score":null,"Total":0}
引用次数: 0
Abstract
Currently, the tumor treatment faces many challenges. Although chemotherapy is the most effective and economical choice, most chemotherapy drugs lack tumor specificity, have low bioavailability, and face many obstacles in clinical application. Significantly, the tumor immunosuppressive microenvironment (TIME) and low immunogenicity in solid tumors also seriously affect the clinical effect of tumor therapy. Here, metal-phenolic network nanoparticles self-assembled by copper-coordinated natural drug chlorogenic acid (ChA) (ChA-Cu NPs) are designed to amplify cell immunogenic death mediated by cuproptosis and pyroptosis for antitumor immunotherapy. Specifically, the synthesized ChA-Cu NPs can disintegrate and release Cu2+ and the polyphenol drug ChA in the tumor microenvironment, realizing the combined chemotherapy/chemodynamic kinetics in the treatment of tumors. Importantly, the release of Cu2+ and ChA can drive the cascade reaction, which can disturb redox homeostasis by producing reactive oxygen species (ROS) and depleting GSH, and induce pyroptosis and make tumor cells more sensitive to cuproptosis. Furthermore, pyroptosis and cuproptosis can evoke immunogenic cell death (ICD) and release damage-associated molecular patterns (DAMPs), stimulating dendritic cells (DCs) to mature and activate CD8+ T cells. It is encouraging that ChA-Cu NPs can reprogram TIME to achieve significant tumor growth inhibition.
期刊介绍:
The Journal of Controlled Release (JCR) proudly serves as the Official Journal of the Controlled Release Society and the Japan Society of Drug Delivery System.
Dedicated to the broad field of delivery science and technology, JCR publishes high-quality research articles covering drug delivery systems and all facets of formulations. This includes the physicochemical and biological properties of drugs, design and characterization of dosage forms, release mechanisms, in vivo testing, and formulation research and development across pharmaceutical, diagnostic, agricultural, environmental, cosmetic, and food industries.
Priority is given to manuscripts that contribute to the fundamental understanding of principles or demonstrate the advantages of novel technologies in terms of safety and efficacy over current clinical standards. JCR strives to be a leading platform for advancements in delivery science and technology.